fluidigm.com - LAB Company Value to Revenue Ratio

Public company logo of Standard BioTools Inc (LAB)

Standard BioTools Inc. (LAB) valuation-to-revenue ratio correlates with geopolitical pressure restricting equipment exports to isolated regions. The -2478.38 mark characterizes this parameter amid cost optimization following the merger of two medtech assets. Meanwhile, high technological sophistication in mass cytometry and the possession of cell analysis patents create significant barriers to entry for new market players.

LAB Standard BioTools Corp Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/19/2026)

Financial and market metric breakdowns for Fluidigm (LAB)

- share price and consensus valuation forecast:
Fundamental company valuation:Standard BioTools Inc. - LAB
Finished products of Standard BioTools Inc

Standard BioTools Inc. (LAB) bases its business on the development of high-tech equipment for spatial biology. The EV/Sales metric compares the total value of assets and debt against the volume of generated sales. An increase in this ratio amid stagnant revenue signals overvaluation and the risk of a sharp price correction. It is critical for investors to track hidden institutional shifts through daily calculations. The current EV to revenue trend reflects market expectations regarding the company's engineering potential.

Competitor analysis for Standard BioTools Inc.

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue